NYSE: CTLT |
| Healthcare / Drug Manufacturers / USA |
100.97 | +4.28 | +4.43% | Vol 669.33K | 1Y Perf -7.20% |
May 26th, 2022 16:04 DELAYED |
BID | 90.67 | ASK | 113.01 | ||
Open | 96.79 | Previous Close | 100.97 | ||
Pre-Market | - | After-Market | 100.97 | ||
- - | - -% |
Target Price | 140.60 | Analyst Rating | Strong Buy 1.32 | |
Potential % | 39.25 | Finscreener Ranking | ★★★★ 53.48 | |
Insiders Trans % 3/6/12 mo. | -/-100/-100 | Value Ranking | ★★★ 50.87 | |
Insiders Value % 3/6/12 mo. | -/-100/-100 | Growth Ranking | ★★★★+ 62.32 | |
Insiders Shares Cnt. % 3/6/12 mo. | -/-100/-100 | Income Ranking | — - | |
Price Range Ratio 52W % | 25.99 | Earnings Rating | Neutral | |
Market Cap | 18.10B | Earnings Date | 3rd May 2022 | |
Alpha | 0.01 | Standard Deviation | 0.11 | |
Beta | 1.44 |
Today's Price Range 96.55101.62 | 52W Range 86.34142.64 | 5 Year PE Ratio Range 24.50112.00 |
Summary:
Neutral
Technical Indicators: | Neutral |
Moving Averages: | Buy |
Performance | |||
---|---|---|---|
1 Week | 0.78% | ||
1 Month | 14.40% | ||
3 Months | -1.35% | ||
6 Months | -23.69% | ||
1 Year | -7.20% | ||
3 Years | 118.41% | ||
5 Years | 180.55% | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | 9.47 | |||
ROE last 12 Months | 11.92 | |||
ROA (5Y Avg) | 1.70 | |||
ROA last 12 Months | 5.21 | |||
ROC (5Y Avg) | 4.50 | |||
ROC last 12 Months | 7.45 | |||
Return on invested Capital Q | 1.91 | |||
Return on invested Capital Y | 2.76 | |||
Assets Turnover | 0.50 | |||
Receivables Turnover | 4.10 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
36.00 | ||||
3.88 | ||||
3.75 | ||||
35.00 | ||||
-15.60 | ||||
2.86 | ||||
34.33 | ||||
25.85 | ||||
21.28B | ||||
Forward PE | 24.51 | |||
PEG | 2.08 |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
2.10 | ||||
2.90 | ||||
0.47 | ||||
0.91 | ||||
6.00 | ||||
Leverage Ratio | 2.30 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
33.80 | ||||
15.70 | ||||
23.20 | ||||
11.30 | ||||
10.85 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
4.70B | ||||
26.24 | ||||
21.60 | ||||
16.88 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q03 2022 | 0.89 | 1.00 | 12.36 |
Q02 2022 | 0.79 | 0.85 | 7.59 |
Q01 2022 | 0.58 | 0.63 | 8.62 |
Q04 2021 | 1.01 | 1.08 | 6.93 |
Q03 2021 | 0.73 | 0.78 | 6.85 |
Q02 2021 | 0.50 | 0.58 | 16.00 |
Q01 2021 | 0.33 | 0.33 | 0.00 |
Q04 2020 | 0.81 | 0.85 | 4.94 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
6/2022 QR | 1.09 | -2.68 | Negative |
6/2022 FY | 3.56 | 2.30 | Positive |
9/2022 QR | 0.69 | 0.00 | - |
6/2023 FY | 4.02 | 1.26 | Positive |
Next Report Date | - |
Estimated EPS Next Report | 0.89 |
Estimates Count | 5 |
EPS Growth Next 5 Years % | 17.30 |
Volume Overview | |
---|---|
Volume | 669.33K |
Shares Outstanding | 179.21K |
Shares Float | 140.79M |
Trades Count | 15.24K |
Dollar Volume | 67.03M |
Avg. Volume | 1.15M |
Avg. Weekly Volume | 880.46K |
Avg. Monthly Volume | 1.32M |
Avg. Quarterly Volume | 1.25M |
Catalent Inc. (NYSE: CTLT) stock closed at 100.97 per share at the end of the most recent trading day (a 4.43% change compared to the prior day closing price) with a volume of 669.33K shares and market capitalization of 18.10B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 17300 people. Catalent Inc. CEO is John R. Chiminski.
The one-year performance of Catalent Inc. stock is -7.2%, while year-to-date (YTD) performance is -21.14%. CTLT stock has a five-year performance of 180.55%. Its 52-week range is between 86.34 and 142.64, which gives CTLT stock a 52-week price range ratio of 25.99%
Catalent Inc. currently has a PE ratio of 36.00, a price-to-book (PB) ratio of 3.88, a price-to-sale (PS) ratio of 3.75, a price to cashflow ratio of 35.00, a PEG ratio of 2.32, a ROA of 5.21%, a ROC of 7.45% and a ROE of 11.92%. The company’s profit margin is 10.85%, its EBITDA margin is 23.20%, and its revenue ttm is $4.70 Billion , which makes it $26.24 revenue per share.
Of the last four earnings reports from Catalent Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.89 for the next earnings report. Catalent Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Catalent Inc. is Strong Buy (1.32), with a target price of $140.6, which is +39.25% compared to the current price. The earnings rating for Catalent Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Catalent Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Catalent Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 11.83, ATR14 : 4.02, CCI20 : 61.91, Chaikin Money Flow : 0.08, MACD : 0.13, Money Flow Index : 45.86, ROC : 6.88, RSI : 55.13, STOCH (14,3) : 92.26, STOCH RSI : 1.00, UO : 51.54, Williams %R : -7.74), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Catalent Inc. in the last 12-months were: Alessandro Maselli (Sold 4 736 shares of value $603 083 ), Aristippos Gennadios (Sold 2 727 shares of value $349 187 ), Gregory T. Lucier (Sold 5 068 shares of value $645 407 ), John R. Chiminski (Sold 0 shares of value $-2 986 972 ), John R. Chiminski (Sold 208 262 shares of value $27 069 357 ), Jonathan Arnold (Sold 0 shares of value $-338 421 ), Jonathan Arnold (Sold 12 905 shares of value $1 782 080 ), Karen A. Flynn (Sold 2 472 shares of value $288 334 ), Kay A Schmidt (Sold 3 563 shares of value $457 590 ), Michael J. Grippo (Sold 4 204 shares of value $544 204 ), Peter Zippelius (Sold 3 487 092 shares of value $437 899 992 ), Ricardo Pravda (Sold 0 shares of value $-241 694 ), Ricardo Pravda (Sold 8 856 shares of value $1 103 071 ), Ricci S Whitlow (Sold 184 shares of value $18 836 ), Ricky Hopson (Sold 4 156 shares of value $473 974 ), Scott Gunther (Sold 5 252 shares of value $667 692 ), Steven L. Fasman (Sold 0 shares of value $-889 050 ), Steven L. Fasman (Sold 46 874 shares of value $5 950 785 ), Thomas P. Castellano (Sold 4 955 shares of value $646 339 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Strong Buy | Strong Buy |
Catalent Inc is a specialty and generic drug manufacturing company. The company focuses on advanced delivery technologies and development solutions for drugs, biologics, and consumer health products. The vast majority of Catalent's sales are generated in the United States, followed by Europe and the rest of the world. Most of the company's sales are derived from branded drug products. The company considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. It operates in four operating segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services.
CEO: John R. Chiminski
Telephone: +1 732 537-6200
Address: 14 Schoolhouse Road, Somerset 08873, NJ, US
Number of employees: 17 300
Thu, 05 May 2022 01:47 GMT Analysts Offer Insights on Healthcare Companies: Catalent (CTLT), PTC Therapeutics (PTCT) and Surgery Partners (SGRY)
- TipRanks. All rights reserved.Tue, 12 Apr 2022 03:36 GMT Catalent (CTLT) Gets a Hold Rating from Deutsche Bank
- TipRanks. All rights reserved.Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. CBOE EDGX Top real-time data for Premium users, NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Technology and data provided by TeleTrader. Conditions of Use. The regulations of the respective stock are to be observed. Copyright © 2022. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.